Can Stevens-Johnson Syndrome Occur After Years on Lamotrigine?
Yes, Stevens-Johnson syndrome (SJS) can occur even after many years of lamotrigine use, though this is extremely rare—the vast majority of cases develop within the first month of therapy.
Timing of Risk
The evidence clearly shows a temporal pattern for lamotrigine-induced SJS:
- Highest risk period: The first 5-28 days after drug initiation 1
- Most cases: Occur within the first 8 weeks of exposure 2
- Late-onset cases: Documented after 6 months of stable use 3
While the UK guidelines emphasize that a latent period of 5-28 days following drug initiation is the most likely timeframe for SJS/TEN development 1, case reports demonstrate that delayed-type hypersensitivity reactions can occur well beyond this window. One documented case showed SJS developing after 6 months of lamotrigine use in a patient who had no initial warning signs during the first half-year of therapy 3.
Risk Factors That Increase Susceptibility
Key factors that elevate risk at any time point:
- Concomitant valproic acid use: The most significant risk factor, present in 19 of 38 cases in a systematic review 4
- Rapid dose titration: Increases risk regardless of treatment duration 4
- Genetic predisposition: HLA-B15:02 (Chinese/Southeast Asian), HLA-B31:01 (Japanese), HLA-B*44:03 (Korean) 5
- Female sex and younger age: More common in lamotrigine-associated cases 6
Clinical Vigilance Required
Warning signs to monitor (even in long-term users):
- Fever preceding skin manifestations
- Mucosal erosions (oral, conjunctival, genital)
- Flat, diffuse erythematous maculopapular rashes
- Targetoid lesions
- Systemic symptoms (malaise, arthralgia)
The systematic review of 38 cases showed that clinical features consistently included mucocutaneous lesions, epidermal detachment, fever, and conjunctivitis, with most patients recovering within 2-3 weeks after drug discontinuation, though two deaths were reported 4.
Immediate Management Protocol
If SJS is suspected in a long-term lamotrigine user:
- Discontinue lamotrigine immediately 1—this is the single most critical intervention
- Calculate SCORTEN within first 24 hours to predict mortality risk 1
- Transfer to burn center or ICU if >10% body surface area involvement 1
- Initiate supportive care: IV fluids, wound care, nutritional support
- Consider systemic corticosteroids and immunoglobulins (though evidence for efficacy remains uncertain) 4
Critical Pitfalls to Avoid
Common mistakes in long-term users:
- Assuming immunity: Long-term tolerance does NOT guarantee permanent safety
- Attributing symptoms to other causes: The rarity of late-onset cases may lead to diagnostic delay
- Continuing the drug: Even a single additional dose can worsen outcomes
- Missing concomitant drug interactions: Adding valproic acid to stable lamotrigine therapy resets the risk window
The Spanish pharmacovigilance data showed lamotrigine was the second most common antiepileptic associated with SJS/TEN reports (37 SJS, 20 TEN cases), with most occurring in the first month but not exclusively 7. Recent data from 2019-2022 shows lamotrigine emerging as an increasingly common cause, accounting for 40% of SJS/TEN cases in one burn center, particularly with off-label psychiatric use 6.
Patient Education Essentials
Counsel all patients on lamotrigine (regardless of duration) to:
- Report any new rash, fever, or mucosal symptoms immediately
- Understand that risk persists throughout treatment, though dramatically lower after initial months
- Avoid restarting lamotrigine without specialized rechallenge protocols if SJS occurs 5
- Inform all healthcare providers about lamotrigine use before starting new medications
The bottom line: While the overwhelming majority of lamotrigine-induced SJS occurs within the first month of therapy 1, 4, 7, documented cases of delayed reactions after 6 months 3 mean that clinicians must maintain vigilance throughout the entire treatment course. Any new mucocutaneous symptoms warrant immediate evaluation and consideration of drug discontinuation.